CNM-Au8 prolonged survival for people with ALS relative to those who received the investigational treatment zilucoplan or a ...

for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company's commitment to advance a new treatment approach for Amyotrophic Lateral Sclerosis (ALS ...

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

QRL-101-04 (NCT06714396) is a Phase 1 PoM single-dose, placebo-controlled clinical trial designed to evaluate the safety and tolerability of QRL-101 in people living with ALS. QRL-101-04 is ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...